[Page Banner Image]

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

[HRule Image]

Molecular Biology — March 2002

BTF Decisive Microbiology is developing its bioparticle dispensing technology platform for quantitative DNA analysis. The technology can be configured in kit format that provides accurate calibration of DNA measurements either from sample to sample, lab to lab or country to country.

Caliper Technologies Corp. has developed two new biological assays for drug screening and a new 12-sipper LabChip device. The Calcium Flux Assay, is now available for purchase as an early release edition and in late stage development is an Ion Channel Assay. Caliper expects shipments of its first 12-sipper LabChip device to begin in 2002.

Ciphergen Biosystems, Inc. and Beckman Coulter, Inc. have formed an alliance to automate clinical proteomics research by combining Ciphergen's biomarker discovery and assay platform with a custom configured version of Beckman Coulter's Biomek 2000 system. The system is optimized for use with the Ciphergen's ProteinChip Biomarker System.

Genaissance Pharmaceuticals, Inc. has announced that an initial analysis of the STRENGTH I Study identified a number of statistically significant associations that link specific genetic markers to changes in the levels of LDL cholesterol, HDL cholesterol and triglycerides in patients taking cholesterol statin drugs.

MDS Proteomics Inc. have identified key regulatory protein switches inside human cells that can be used to distinguish between healthy and diseased cells and to uncover the key protein targets against which new drugs will be made.

The Mayo Clinic and Millennium Pharmaceuticals, Inc. are developing genomic markers that may be able to predict responsiveness to the most common ovarian cancer chemotherapy regime, platinum-paclitaxel. Although this is the most common form of treatment for epithelial ovarian cancer, and most women derive some benefit, only 15% of advanced-stage cases are cured with this approach.

[HRule Image]

* Molecular Biology - February 2002
* Molecular Biology - January 2002
* Molecular Biology - December 2001
* Molecular Biology - November 2001
* Molecular Biology - October 2001
* Molecular Biology - September 2001
* Molecular Biology - Summer 2001
* Molecular Biology - May 2001
* Molecular Biology - April 2001
* Molecular Biology - March 2001
* Molecular Biology - February 2001
* Molecular Biology - January 2001
* Molecular Biology - December 2000
* Molecular Biology - November 2000
* Molecular Biology - October 2000
* Molecular Biology - September 2000
* Molecular Biology - July - August 2000
* Molecular Biology - June 2000
* Molecular Biology - May 2000
* Molecular Biology - April 2000
* Molecular Biology - March 2000
* Molecular Biology - Febuary 2000
* Molecular Biology - January 2000
* Molecular Biology - December 1999
* Molecular Biology - November 1999
* Molecular Biology - October 1999
* Molecular Biology - September 1999

[HRule Image]

Home | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-2002 STRATCOM

Last modified: April 01, 2002